Zanzalintinib in combination with atezolizumab demonstrated a statistically significant reduction in risk of death versus regorafenib in intent-to-treat population ALAMEDA, Calif. / Jun 22, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ® ) demonstrated a statistically... Read More

A regulatory decision by the European Medicines Agency is anticipated in 2025 In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting ALAMEDA, Calif. / Jun 20, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX ®... Read More

Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% Additional results from dose-finding cohorts will also be presented ALAMEDA, Calif. / May 22, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo ®... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / May 22, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6 th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27.... Read More

Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million Conference Call and Webcast Today at 5:00 PM Eastern Time ALAMEDA, Calif. / May 13, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / May 07, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas. RBC Capital Markets 2025 Global... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Apr 29, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status Exelixis is prepared to... Read More

Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for investigation in patients with advanced solid tumors ALAMEDA, Calif. / Mar 25, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Feb 25, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 45 th Annual Health Care Conference: Exelixis is scheduled to present at 9:50 a.m. ET / 6:50 a.m. PT on Tuesday, March 4 in Boston. Barclays 27 th Annual Global... Read More

Completion of currently ongoing stock repurchase program expected in the second quarter of 2025 ALAMEDA, Calif. / Feb 20, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans on completing the currently ongoing $500 million stock... Read More

After more than five years of follow-up, CABOMETYX in combination with Opdivo continued to show survival benefit compared with sunitinib Long-term efficacy seen across subgroups, including site of metastases ALAMEDA, Calif. / Feb 15, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX ® (cabozantinib) in combination with Opdivo... Read More

Presentation to be webcast on www.exelixis.com ALAMEDA, Calif. / Feb 13, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors &... Read More

Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Jan 28, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a... Read More

In a subgroup analysis of patients without liver metastases, adding atezolizumab to zanzalintinib led to enhanced progression-free survival and overall survival ALAMEDA, Calif. / Jan 25, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab (Tecentriq ® ) in patients with... Read More

Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors Supplemental New Drug Application under review with the U.S. FDA for cabozantinib for the treatment of patients with advanced neuroendocrine tumors based on findings from CABINET ALAMEDA, Calif. / Jan 24, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today... Read More

Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion Presentation and webcast at 43 rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13 th at 5:15 p.m. PT / 8:15 p.m. ET ALAMEDA, Calif. / Jan 12, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today... Read More

ALAMEDA, Calif. / Jan 09, 2025 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX ® ) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Nov 27, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36 th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global... Read More

ALAMEDA, Calif. / Nov 26, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX ® ) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Nov 07, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim’s Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston. Stifel 2024... Read More

Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 Increasing Total Revenues and Net Product Revenues Guidance Favorable Ruling on Cabozantinib Patent Litigation Received from U.S. District Court Collaboration with Merck Expands Zanzalintinib Development Program Conference Call and Webcast Today at 5:00 PM Eastern Time... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Oct 15, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

ALAMEDA, Calif. / Oct 15, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN) , Civil Action No. 22-00228 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to three Orange Book-listed patents related to cabozantinib, including U.S. Patents No.... Read More

ALAMEDA, Calif. & RAHWAY, N.J. / Oct 14, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in a... Read More

Cabozantinib continues to demonstrate a significant improvement in progression-free survival versus placebo in patients with advanced neuroendocrine tumors, including across key subgroups Findings were the basis for the supplemental New Drug Application filed with the U.S. Food and Drug Administration for cabozantinib for advanced neuroendocrine tumors ALAMEDA, Calif. / Sep 16, 2024 / Business Wire / Exelixis, Inc. (Nasdaq:... Read More

ALAMEDA, Calif. / Sep 15, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX ® ) in combination with atezolizumab (Tecentriq ® ) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Aug 28, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan Stanley 22 nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 9:15 a.m. ET / 6:15 a.m. PT on Wednesday, September 4 in New York City. 2024... Read More

Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million G0AAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application (sNDA) for Cabozantinib in Advanced Neuroendocrine Tumors (NET) Earned $150 million Cabozantinib Sales-Based Milestone from Ipsen Completed $450 million Stock Repurchase Program for 2024... Read More

The FDA assigned a Prescription Drug User Fee Act target action date of April 3, 2025 Application is based on results from the phase 3 CABINET pivotal trial, in which cabozantinib provided a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ALAMEDA, Calif. / Aug 06, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that its supplemental New Drug... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Jul 23, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

Presentation to be webcast on www.exelixis.com ALAMEDA, Calif. / May 28, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44 th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar... Read More

ALAMEDA, Calif. / May 20, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib)... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / May 07, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20 p.m. ET / 11:20 a.m. PT on Tuesday, May 14 in Las Vegas. Citizens JMP... Read More

Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million Restructuring Expenses of $32.8 million Recorded GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.17 Conference Call and Webcast Today at 5:00 PM Eastern Time ALAMEDA, Calif. / Apr 30, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Apr 16, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Feb 27, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March: TD Cowen 44 th Annual Health Care Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Tuesday, March 5 in Boston. Leerink... Read More

Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 GAAP Diluted EPS of $0.27 for the Fourth Quarter of 2023, $0.65 for the Fiscal Year 2023 Non-GAAP Diluted EPS of $0.33 for the Fourth Quarter of 2023, $0.90 for the... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Feb 01, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Thursday, February... Read More

Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer Findings to be presented during an oral presentation at ASCO GU 2024 ALAMEDA, Calif. / Jan 25, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX ® )... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Jan 23, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will be released on Tuesday, February 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a... Read More

ALAMEDA, Calif. / Jan 18, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO). The three-member panel of the... Read More

Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise... Read More

Presentation to be webcast on www.exelixis.com ALAMEDA, Calif. / Jan 02, 2024 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT / 7:30 p.m. ET. To access the webcast link, log onto... Read More

ALAMEDA, Calif. / Dec 07, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing research and development pipeline, highlight recent clinical updates and elaborate on the... Read More

STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated in these tumors ALAMEDA, Calif. / Dec 04, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus... Read More

Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 ALAMEDA, Calif. & HAYWARD, Calif. / Dec 04, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor (TKI), in... Read More

Presentation to be webcast on www.exelixis.com ALAMEDA, Calif. / Nov 21, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28 at 11:00 am ET / 8:00 am PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors &... Read More

Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% Anti-tumor activity was observed in patients who had progressed on prior VEGFR-tyrosine kinase inhibitors, including cabozantinib ALAMEDA, Calif. / Nov 10, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from an expansion cohort of STELLAR-001... Read More

Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million Conference Call and Webcast Today at 5:00 PM Eastern Time ALAMEDA, Calif. / Nov 01, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline... Read More

Cabozantinib compared with placebo reduced the risk of disease progression or death in patients with pancreatic NET and in patients with extra-pancreatic NET Exelixis will discuss the results with the U.S. Food and Drug Administration ALAMEDA, Calif. / Oct 22, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ® )... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Oct 18, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2023 financial results will be released on Wednesday, November 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models In April 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico’s Investigational New Drug application (IND) for ISM3091 in patients with solid tumors ALAMEDA, Calif. & NEW YORK / Sep 12, 2023 / Business... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / Aug 31, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September: 2023 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Friday, September 8 in Everett, MA. Morgan... Read More

CABINET trial will be unblinded and stopped early due to a dramatic improvement in efficacy per a unanimous recommendation by The Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board Based on positive results, findings will be discussed with the U.S. Food and Drug Administration ALAMEDA, Calif. / Aug 24, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that the Alliance... Read More

Dr. Peterson’s extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios ALAMEDA, Calif. / Aug 23, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran... Read More

Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer A trend toward improvement in overall survival was observed at first interim analysis Findings will be presented at an upcoming medical meeting and discussed with health... Read More

Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31 Conference Call and Webcast Today at 5:00 PM Eastern Time ALAMEDA, Calif. / Aug 01, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate... Read More

ALAMEDA, Calif. / Jul 23, 2023 / Business Wire / Exelixis, Inc . (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva). This settlement resolves patent litigation brought by Exelixis in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Jul 18, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / May 30, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June: William Blair 43 rd Annual Growth Stock Conference: Exelixis is scheduled to present at 10:20 am ET / 9:20 am CT/ 7:20 am PT on Tuesday, June 6 in Chicago.... Read More

Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 Conference Call and Webcast Today at 5:00 PM Eastern Time ALAMEDA, Calif. / May 09, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate... Read More

ALAMEDA, Calif. / May 07, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately. The Board recommends shareholders vote in favor of its remaining 10 director nominees and will not contest the election of Farallon Capital Management’s (“Farallon”) additional nominee, David... Read More

Presentations to be webcast on www.exelixis.com ALAMEDA, Calif. / May 03, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m. ET / 10:40 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the... Read More

Files Definitive Proxy Materials and Sends Letter to Exelixis Shareholders Encourages Shareholders to Show that the Status Quo Cannot Continue by Voting to Elect All Three of Farallon’s Independent Nominees on the WHITE Proxy Card Visit www.FocusEXEL.com to Obtain Important Information and Sign Up for Updates SAN FRANCISCO / May 03, 2023 / Business Wire / Funds managed by Farallon Capital Management, L.L.C. (“Farallon”) own... Read More

Urges Shareholders to Vote "FOR" All of Exelixis’ 11 Recommended Director Nominees on the GOLD Proxy Card ALAMEDA, Calif. / May 01, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that it has filed its definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which will be held on May... Read More

Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT ALAMEDA, Calif. / Apr 25, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business... Read More

ALAMEDA, Calif. / Apr 13, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”). As part of its ongoing refreshment program, the Board is recommending Tomas Heyman,... Read More

Responds to Letter from Farallon Capital Management ALAMEDA, Calif. / Apr 05, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today issued the following statement in response to the letter issued by Farallon Capital Management, L.L.C. (“Farallon”): Successfully Executing Strategy with Robust, Balanced Capital Plan Exelixis is executing a clear strategy to drive growth and to create meaningful value for... Read More

Believes the Company Must Focus R&D Efforts and Spending, Communicate a Coherent Strategy and Return Excess Capital to Shareholders in Order to Reverse Exelixis’ Track Record of Underperformance Intends to Nominate Three Accomplished, Independent Director Candidates Who Will Bring New Perspectives to the Boardroom to Help Drive Change and Promote Accountability to Shareholders SAN FRANCISCO / Apr 05, 2023 / Business Wire /... Read More

ALAMEDA, Calif. / Mar 13, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.... Read More

ALAMEDA, Calif. / Mar 02, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 evaluated cabozantinib (CABOMETYX ® ) in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell... Read More

ALAMEDA, Calif. & ROTTERDAM, The Netherlands / Feb 13, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the U.S. Food and Drug Administration (FDA) has cleared Sairopa’s Investigational New Drug (IND) Application to evaluate the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors. As a monoclonal antibody active against all human alleles of SIRPα,... Read More

ALAMEDA, Calif. / Feb 07, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “Exelixis had a productive fourth quarter and full year 2022 as we continued to grow the cabozantinib commercial franchise... Read More

ALAMEDA, Calif. / Feb 02, 2023 / Business Wire / Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February: Guggenheim Healthcare Talks Oncology Day 2023: Exelixis is scheduled to present at 11:20 am ET / 8:20 am PT on Thursday, February 9 in New York. SVB Securities Global Biopharma Conference: Exelixis is... Read More

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. ( MSN ), Action No. 19-2017 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to the cabozantinib compound patent (U.S. 7,579,473). The District Court’s decision follows an earlier Stipulation and Order of October 1, 2021,... Read More

Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 Full year 2023 net product revenues guidance of $1,575 million - $1,675 million Corporate priorities for 2023 include readout of Phase 3 trials for cabozantinib, expansion of the Phase 3 program for zanzalintinib, progression of XB002 into full... Read More

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15pm ET / 5:15pm PT. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please... Read More

STELLAR-304 is the second phase 3 pivotal trial evaluating zanzalintinib, a next-generation tyrosine kinase inhibitor in development for multiple advanced tumor types Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC). Zanzalintinib,... Read More

ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) versus docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) without actionable mutations who experienced... Read More

In the QUARTZ-101 trial, XL102 — a novel cyclin-dependent kinase 7 inhibitor — was well tolerated at evaluated dose levels ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclin-dependent kinase 7 (CDK7)... Read More